Data Released at ASCO Demonstrates the Severe Unmet Need in Brain Cancer; DelMar Presented Promising Early Data-

Data Released at ASCO Demonstrates the Severe Unmet Need in Brain Cancer; DelMar Presented Promising Early Data

Report is Available for Download at: www.lifesciadvisors.com/clients/demar

Editor’s Note:

Jeffrey Bacha, B.Sc., MBA, DelMar’s President & CEO, will present at RetailInvestorConferences.com.

DATE: June 6, 2013

TIME:    10:45 AM EDT

LINK:    www.retailinvestorconferences.com > click on the red “register / watch event now” button

This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the company’s “virtual trade booth.” If attendees are not able to join …

Rockwell Medical Announces Completion of Dosing for Phase III CRUISE-1 Study – Efficacy Data Expected in July-

Rockwell Medical Announces Completion of Dosing for Phase III CRUISE-1 Study; Efficacy Data Expected in July

On May 29, Rockwell Medical (Nasdaq: RMTI) announced the completion of patient dosing in CRUISE-1, the first of two Phase III trials for SFP. SFP is the Company’s novel iron replacement product for patients with chronic kidney disease who are receiving hemodialysis. CRUISE-1 data are expected in July, and data from the second Phase III study, CRUISE-2, are expected in October.

Patient Dosing Completed in CRUISE-1. Rockwell Medical achieved a major milestone completing dosing for the first of two Phase III efficacy trials for …

LifeSci Advisors Outstanding 2013 ASCO Abstracts-

LifeSci Advisors Outstanding 2013 ASCO Abstracts

The 2013 American Society of Clinical Oncology (ASCO) Meeting is scheduled for May 31-June 4 in Chicago at the McCormick Place Convention Center. A number of exciting abstracts will be presented, including data from DelMar Pharmaceuticals, Innate Pharma, MethylGene, Sorrento Therapeutics, and Stemline Therapeutics.

A Schedule of ASCO Presentations for these Companies is as follows. Full abstracts are below.

-DelMar Pharmaceuticals (DMPI)-

Title:  Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma or progressive secondary brain tumor.

Abstract No:  2093

Track:  Central Nervous System Tumors

Session:  Central Nervous …

Anthera Announces First Quarter Financial Results and Provides a Corporate Update-

Anthera released first quarter 2013 financial results on May 13, 2013, reporting a strong cash position and decreased operating costs compared to 2012. Anthera has initiated a Phase III trial in patients with clinically active systemic lupus erythematosus (SLE) that are taking corticosteroids, and will begin enrollment this quarter for a Phase II trial in patients with IgA neuropathy. Both trials will test lead candidate blisibimod.

Operating Costs Drop and Cash Position Increases in 1Q2013. Total loss from operations was $6.9 million for the first quarter of 2013, down from $20.1 million in the first quarter of 2012. The …

Rockwell Medical Completes Financing; now Fully-funded Through NDA Filing-

Rockwell Medical Completes Financing; now Fully-funded Through NDA Filing

On May 15, Rockwell Medical (Nasdaq: RMTI) announced the successful closing of a $35.0 million public offering of common stock. Along with the underwriter’s over-allotment option, net yield on the transaction was about $37.8 million. This financing removes a significant overhang from the stock and sets the stage for the release of Phase III CRUISE data in Q3 2013.

Financing Strengthens Rockwell’s Balance Sheet. On May 15^th, 2013, Rockwell Medical announced that it had set a price for a public sale of common stock. The Company issued 11,475,410 shares …

TiGenix Announces Q1 2013 Results-

TiGenix Announces Q1 2013 Results

-ChondroCelect Sales Increased by 55%-

On May 14, 2013, TiGenix (TIG.BR) announced financial results for the first quarter of 2013 and provided a corporate update. The Company continues to see increasing revenue for ChondroCelect, and obtained reimbursement for the product in Spain. TiGenix ended the quarter with €6.8 million ($8.8 million) in cash on hand. In April it received the last tranche of €1 million of a soft loan to support the Phase III of lead product Cx601.

ChondroCelect Sales Continue to Grow, with a 55% Increase over the Prior Year’s Period. In Q1 2013,sales …

Ablynx Announces Quarterly Results and Corporate Update-

Ablynx Announces Quarterly Results and Corporate Update

-Start of Pre-Clinical Work on Nanobody for Severe Allergic Asthma-

-Recent Financing puts Ablynx on Strong Financial Footing-

Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx

On May 15, Ablynx (Euronext: ABLX.BR) announced financial results and a corporate update for the first quarter of 2013. The Company ended the quarter with €82.2 million in cash and equivalents, putting them in a strong position to execute on their development strategy for leading Nanobody therapeutics, which currently includes five clinical programs across multiple indications. Ablynx also recently announced the start of pre-clinical development with its anti-IgE …

LIFESCI ADVISORS INITIATES COVERAGE OF PROTHENA CORPORATION-

LIFESCI ADVISORS INITIATES COVERAGE OF PROTHENA CORPORATION

Recent Elan Spin-Out is Well Capitalized with $120 Million in Cash

Lead Development Program, NEOD001 for Amyloidosis, is in Phase I Testing

www.lifesciadvisors.com/clients/prothena/

 LifeSci Investment Abstract

Prothena (NASDAQ: PRTA) is a biotechnology company developing a new class of antibodies that target misfolded, disease-causing proteins. Their lead drug NEOD001, which entered into a Phase I trial in April 2013, attacks proteins implicated in AL and AA amyloidosis. The second product, with Phase I trials planned for 2014, targets a key protein implicated in Parkinson’s disease. Prothena was spun off from Elan Pharmaceuticals at …

Celsus Announces Interim Phase II Data for MRX-6 to Treat Allergic Contact Dermatitis-

Celsus Announces Interim Phase II Data for MRX-6 to Treat Allergic Contact Dermatitis

Report is Available for Download at: www.lifesciadvisors.com/clients/celsus/

On May 8, Celsus Therapeutics (OTCQB: MRRBY) announced interim results from the 2% dose cohort in their Phase II trial of MRX-6 to treat allergic contact dermatitis (ACD). Patients experienced a statistically significant 56% improvement in symptoms from baseline for their treated hand or forearm compared to a 24% improvement for the control hand or forearm (p<0.001). This improvement is comparable or better than that achieved in similar recent dermatitis trials.

MRX-6 Produced Significant Patient Benefit in Phase II Testing. …

LIFESCI ADVISORS INITIATES COVERAGE OF LIPOCINE INC-

LIFESCI ADVISORS INITIATES COVERAGE OF LIPOCINE INC

-Potential Best-in-Class Oral Testosterone Replacement Therapy Poised for Phase III Trial-

-Pipeline Candidates include Once-Daily Oral TRT and Potential First Oral Drug for the Prevention of Preterm Birth-

Report is Available for Download at: lifesciadvisors.com/clients/lipocine

LifeSci Investment Abstract

Lipocine Incorporated is a biopharmaceutical company dedicated to becoming a leader in certain sectors of men’s and women’s health. The Company’s lead product candidate LPCN 1021 is an oral testosterone replacement therapy that has successfully completed a Phase II trial. In December 2012, Lipocine announced that the FDA has cleared LPCN 1021 to begin …

LifeSci Advisors Initiates Coverage of BrainStorm Cell Therapeutics-

LifeSci Advisors Initiates Coverage of BrainStorm Cell Therapeutics

-Positive Phase I/II Results of   NurOwn^TM Cell Therapy for ALS Presented at AAN-

Report is Available for Download at: www.lifesciadvisors.com/clients/brainstorm/

LifeSci Investment Abstract

BrainStorm Cell Therapeutics (OTC QB: BCLI) is a biotechnology company with a unique approach to treating debilitating neurodegenerative diseases. Positive Phase I/II safety and efficacy results were announced in March 2013 for the Company’s stem cell technology as a treatment for amyotrophic lateral sclerosis (ALS). A new Phase IIa study was initiated in December 2012 and a second Phase II trial is slated to begin in late …

TiGenix Releases Positive Phase IIa Results Using Allogeneic Stem Cells in Refractory Rheumatoid Arthritis-

TiGenix Releases Positive Phase IIa Results Using Allogeneic Stem Cells in Refractory Rheumatoid Arthritis.

-Cx611 is Save and Appears to be Effective based on ACR, EULAR, and DAS28 Responses-
-Promising Data Collected in Refractory Patient Population-

Report is Available for Download at: www.lifesciadvisors.com/clients/tigenix

On April 22, 2013 TiGenix NV (NYSE Euronext: TIG.BR) reported positive results from a Phase IIa study in patients with refractory rheumatoid arthritis using Cx611, which employs allogeneic adipose-derived stem cells. The data demonstrates that Cx611 is safe, and an initial indication of therapeutic efficacy was also reported.

TiGenix Reports Successful Phase IIa Trial of Cx611 in …

Innate Pharma Presents New Data at Two Conferences Highlighting Pre-clinical Programs-

Innate Pharma Presents New Data at Two Conferences Highlighting Pre-clinical Programs Targeting Cancer & Inflammation

On April 10, 2013 Innate Pharma (Euronext: IPH.PA) announced new pre-clinical data at the 2013 American Association for Cancer Research (AACR) Annual Meeting for the IPH41 antibody targeting killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2), which is overexpressed in T lymphoma/leukemia subtypes. The company also presented pre-clinical data on April 12, 2013 at the Molecular Pattern Recognition Receptors Meeting for IPH33, targeting inflammation via the Toll-like receptor 3 (TLR3).

Targeting KIR3DL2 Induces Tumor Cell Death In Mice Xenografts and Ex Vivo Patient Samples. Innate presented data …

DelMar Pharmaceuticals Announces Encouraging Phase I-II GBM Data at AACR-

DelMar Presents Interim Clinical Data for Brain Cancer Drug VAL-083 at American Association of Cancer Research (AACR) Meeting

Report is Available for Download at: www.lifesciadvisors.com/clients/delmar

On April 10, 2013, DelMar Pharmaceuticals (OTC BB: DMPI) presented clinical data at the 2013 AACR Annual Meeting from a Phase I/II clinical trial of VAL-083, a first-in-class chemotherapy for the treatment of glioblastoma multiforme (GBM). The new data demonstrates that VAL-083 is safe and well tolerated at the doses tested to date and there was an initial efficacy signal.

VAL-083 Phase I/II Dose Escalating Study.DelMar initiated a Phase I/II clinical trial of VAL-083 …

LifeSci Advisors Initiates Coverage of Celsus Therapeutics-

LifeSci Advisors Initiates Coverage of Celsus Therapeutics

-Clinical Data from a Phase IIb Study of MRX-6, a First-in-Class Secretory PhospholipaseA₂ Inhibitor for Contact Dermatitis, Expected in H2 2013-

Report is Available for Download at: www.lifesciadvisors.com/clients/celsus/

LifeSci Investment Abstract

Celsus Therapeutics is focused on the development of a new class of anti-inflammatory drugs known as Multi-Functional Anti-Inflammatory Drugs or MFAIDs. The Company has two lead drug candidates in Phase II clinical trials: MRX-6, a topical cream for contact dermatitis& MRX-4, a nasal spray for allergic rhinitis.

Key Points of Discussion

Overview of Celsus’s Strategy. Celsus is developing a platform …